Hello, everyone, and how are you today? We are just fine, thank you, despite daunting weather that altered travel plans. Nonetheless, we managed to arrive at the JP Morgan health care fest, albeit not as soon as we hoped, and plan to scurry about meeting interesting people. As we indicated previously, this will call for sporadic posting. Nonetheless, we have assembled the usual menu of tidbits. We will now search for a cup of stimulation. Have a grand day and do keep in touch …
Johnson & Johnson is set to issue a report next month outlining how much it has raised US prices for its prescription drugs, the Wall Street Journal writes. The report will provide the average increase in list prices, as well as average prices after the discounts given by the health care giant. But J&J is not pledging to hold price hikes to single-digit increases, because the company maintains it already does so.
Regeneron Pharmaceuticals chief executive Len Schleifer called out Amgen for its insistence on blocking sales of a rival Regeneron cholesterol drug during an ongoing court battle over patent infringement, Reuters tells us. A federal judge last week ruled issued an injunction on sales of Praluent, a Regeneron and Sanofi drug, because it infringed patents for Amgen’s Repatha treatment. Regeneron and Sanofi have 45 days to successfully appeal.
About the Author Reprints
